Transforming ovarian cancer care by targeting minimal residual disease
Name
nihms-1989949.pdf
Description
Accepted version
Size
829.29 KB
Format
Adobe PDF
Checksum (MD5)
17e21007f03371b341321cf886eb2fc7
Author(s)
Jazaeri, Amir A
Grisham, Rachel
Knisely, Anne
Spranger, Stefani
Zamarin, Dmitriy
Hillman, R Tyler
Lawson, Barrett C
Burns, Kathleen H
Lee, Sanghoon
Westin, Shannon N
Date Issued
November 10, 2023
Journal
Med
Publisher
Elsevier BV
Citation
Jazaeri, Amir A, Grisham, Rachel, Knisely, Anne, Spranger, Stefani, Zamarin, Dmitriy et al. 2023. "Transforming ovarian cancer care by targeting minimal residual disease." Med, 4 (11).
Version
Author's final manuscript
Abstract
Frontline treatment and resultant cure rates in patients with advanced ovarian cancer have changed little over the past several decades. Here, we outline a multidisciplinary approach aimed at gaining novel therapeutic insights by focusing on the poorly understood minimal residual disease phase of ovarian cancer that leads to eventual incurable recurrences.
MIT Department
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution-Noncommercial-ShareAlike
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1016/j.medj.2023.08.004
